In xenograft models, cMet inhibitors (anti-HGF, anti-MET, and MET-targeted small molecule inhibitors) decrease tumour progression and the expression of stem markers such as CD133, Sox2, and Nanog [182]. This evidence concerns the gene MET and neoplasm.